HIV and increased risk of cardiovascular diseases

Sexual Health

Volumn 2, Issue 4, 2005, Pages 219-221

  Das, Satyajit ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Antiretroviral; Cardiovascular disease; Risk factors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; RISK FACTOR;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; PROTEASE INHIBITORS; RISK FACTORS;

EID: 33644863699     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH05033     Document Type: Review

References (25)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9. doi: 10.1016/SO140-6736(98)08468-2
2. Shahmanesh M, Das S, Stolinski M, Shojaee-Moradie F, Jackson NC, Jefferson W, et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 2005; 90(2): 755-60. doi: 10.1210/jc.2004-1273
3. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003; 168(1): 107-13. doi: 10.1016/S0021-9150(03)00058-3
4. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118(Suppl 2): 23-8. doi: 10.1016/j.amjmed.2004.11.016
5. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479-86. doi: 10.1097/00002030-200311210- 00010
6. Iloeje U, Yuan Y, L'ltalien G, Mauskopf J, Holmberg SD, Moorman AC, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6(1): 37-44. doi: 10.1111/j. 1468-1293. 2005.00265.x
7. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Synclr 2003; 33(4): 506-12.
8. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Synclr 2002; 30(5): 471-7.
9. El-Sadr W, Reiss P, De Wit S, D'Arminio Monforte A, Thiébaut R, Morfeldt L, et al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005, Boston. Abstract 42.
10. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-10. doi: 10.1056/NEJMoa022048
11. Sabin C, Morfeldt L, Friis-Møller N, Rickenbach M, Reiss P, D'Arminio Monforte A, et al. Changes over time in the use of antiretroviral therapy and risk factors for cardiovascular disease in the D:A:D Study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005, Boston. Abstract 866.
12. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-62.
13. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: F123-8. doi: 10.1097/00002030-200011100- 00001
14. Thiébaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al. The changing face of cardiovascular risk in HIV-infected patients. ANRS Aquitaine Cohort, 2003. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005, Boston. Abstract 871.
15. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Synclr 2005; 38(2): 115-23. doi: 10.1097/01.qai.0000147525. 26746.07
16. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent choesteryl ester accumulation in macrophages. J Clin Invest 2003; 111: 389-97. doi: 10.1172/JCI200316261
17. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88(4): 1907-10. doi: 10.1210/jc.2002-021922
18. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron Artery Dis 2000; 11:41-6. doi: 10.1097/00019501- 200002000-00008
19. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987 May 29; 59(14):91G-94G.
20. Kamin DS, Steven K. Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19(7): 641-52. doi: 10.1097/01.aids.0000166087.08822.bc
21. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19(7): 685-94. doi: 10.1097/01.aids.0000166091.39317.99
22. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Gladys E, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfmavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Synclr 2004, 35(1): 22-32. doi: 10.1097/00126334-200401010-00003
23. Noor MA, Seneviratne T, Aweeka FT, Lo J, Schwarz J-M, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS2002; 16: Fl-8. doi: 10.1097/00002030-200203290-00002
24. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292: 191-201. doi: 10.1001/jama.292.2.191
25. Van der Valk M, Kastelein J.T, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14. doi: 10.1097/00002030-200112070-00008